FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.
Cytophage Technologies (TSXV: CYTO) has seen early success in a recently completed human trial conducted at The Ottawa Hospital. The trial, which saw the use of its phages for the treatment of an antibiotic-resistant prosthetic joint infection, was the first time in Canada that phages were used for the treatment of a joint replacement infection.
The single subject clinical trial was devised between The Ottawa Hospital Research Institute and Health Canada following the patient being subjected to fifteen surgeries in an effort to treat the antibiotic resistant infection. Lead by Dr Marisa Azad, the landmark trial saw phages developed by Cytophage administered for several weeks via direct injection and an IV line.
The patient is now said to be improving, with inflammation in her body decreasing following the treatment.
“We are incredibly proud of our team who has been able to develop and provide this therapy. Now that this trial is gaining so much attention from the news media, there is a much larger spotlight on Cytophage, which became the first Canadian phage company to go public,” commented Dr Steven Theriault, CEO of Cytophage.
Given the landmark nature of the trial, the study has been featured by multiple media outlets, including CBC The National, CTV Winnipeg, CBC News, and CTV National News.
Further details on the clinical trial are expected to be released at a later date.
Cytophage Technologies last traded at $0.57 on the CSE.
FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
